

ANGIOGENIN: A NEW VASCULARIZATION MARKER IN COLORECTAL CARCINOMA

Essay

Submitted for the Partial Fulfillment of Master Degree
in *Clinical and Chemical Pathology*

Presented By

Magy Samir Maiz Girgis
M.B.B. Ch.

Under the Supervision of

Professor Sawsan Said Hafez

Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

Doctor Manal Mohamed Abd Al-Aziz

Assistant Professor of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

Doctor Eman Saleh El-Hadidi

Lecturer of Clinical and Chemical Pathology
Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2005

List of Abbreviations

AAPC	: Attenuated form of adenomatous polyposis coli.
aFGF	: acidic fibroblast growth factor.
Ang	: Angiopoietin
APC	: Adenomatous polyposis coli
Asn	: Asparagine
b-FGF	: basic fibroblast growth factor.
CA19.9	: Carbohydrate antigen 19.9
cDNA	: Complementary deoxyribonucleic acid
CEA	: Carcinoembryonic antigen.
CT	: Computerized tomography
DCBE	: Double contrast barium enema.
DCC	: Deleted in colorectal cancer
DNA	: Deoxyribonucleic acid
ELISA	: Enzyme linked immunosorbent assay
FAP	: Familial adenomatous polyposis
FGF	: Fibroblast growth factor.
FGF-BP	: Fibroblast growth factor binding protein
FGFR	: Fibroblast growth factor receptor.
FOBT	: Fecal occult blood test
Gly	: Glycine
HCC	: Hepatocellular carcinoma
HGF	: Hepatocyte growth factor.
HIF-1	: Hypoxia-inducible factor-1
His	: Histidine
HNPCC	: Hereditary non polyposis colotectal cancer.
KDa	: Kilo Dalton.
LOH	: Loss of heterozygosity
Lys	: Lysine
MIN	: Microsatellite instability
MMP	: Matrix metalloproteinase

MMR	: Mismatch repair
mRNA	: Messenger ribonucleic acid
NLS	: Nuclear localization sequence
NSAIDs	: Non steroidal antiinflammatory drugs
NSCLC	: Non-small cell lung cancer
PAI-1	: Plasminogen activator inhibitor type-1
PCR	: Polymerase chain reaction
PD-ECGF	: Platelet derived endothelial cell growth factor.
PDGF	: Platelet derived growth factor.
PDGF-R	: Platelet derived growth factor receptor.
PDGF-RB	: Platelet derived growth factor receptor beta
PDR	: Proliferative diabetic retinopathy
PLC	: Phospholipase C
PMHR	: Postmolar gestational trophoblastic tumor
PMN	: Polymorph nuclear
Rb	: Retinoblastoma
RER+ve	: Replication error positive.
RNase	: Ribonuclease
r-RNA	: Ribosomal ribonucleic acid
RRRGL	: R: Arginine G: Glycine
SCLC	: Small cell lung cancer
TGF	: Transforming growth factor
Th	: T helper
TNF	: Tumor necrosis Factor
TNM	: Tumor Node Metastasis
t-RNA	: Transfer ribonucleic acid
TSP	: Thrombospondin
VEGF	: Vascular endothelial growth factor
VEGF-R	: Vascular endothelial growth factor receptor.

List of contents

List of tables

List of Figures

List of Abbreviations

Introduction and aim of the study	1
I. Colorectal cancer	4
A. Epidemiology and risk factors of colorectal cancer	4
B. Pathology of colorectal cancer	14
C. Clinical manifestations	26
D. Screening and diagnostic Procedures	28
E. Genetics of colorectal cancer	34
II. Tumor Angiogenesis	42
A. Angiogenesis and vasculogenesis	42
B. Mechanism of tumoral angiogenesis	45
C. Angiogenic Factors.	48
D. Antiangiogenic factors	76
F. Methods of assay	86
III. Angiogenin	88
A. Structure	88
B. Specific receptors and signaling	89
C. Nuclear transport	90

D. Intranuclear mode of action	92
E. Angiogenic function	92
F. Other biological functions of angiogenin	94
g. Angiogenin in different physiological and pathological conditions	95
h. Assay of angiogenin	106
I. Targeting angiogenesis	114
 Summary and Conclusion	118
Recommendations.....	121
References	122
Arabic Summary	

List of Tables

Table	Title	Page
1	Classification of colorectal tumors	16
2	Astler coller Modification of Dukes' staging system for colorectal cancer	17
3	TNM staging system for colorectal cancer	18
4	World Health Organization classification of the colon and rectum	20
5	The best defined angiogenic and antiangiogenic factors	49
6	Angiogenic factors in common human cancers and correlation with tumor progression or patient survival	74
7	Mean serum angiogenin concentrations and mean tissue angiogenin amounts in the cancer group	103
8	Principle angiogenesis inhibitors in colorectal cancer	116

List of Figures

Fig.	Title	Page
1	Risk of colorectal cancer development	7
2	Distribution of colorectal cancer	15
3	Stage groupings of colorectal cancer	19
4	A genetic model for colorectal cancer tumorigenesis	35
5	Emerging details of APC function suggest molecular mechanisms by which the gene may act as a tumor suppressor	37
6	Details of p53 function suggest both direct and indirect modes of tumor suppression	40
7	Steps of vasculogenesis and angiogenesis	44
8	Four mechanisms by which tumor may stimulate or contribute to angiogenesis	47
9	Stepwise progression in cancer development	47
10	The sequential model of the angiogenic cascade during tumor angiogenesis	48
11	Vascular endothelial growth factor ligands and their receptors	50
12	Structure of PDGF-BB	56
13	A diagrammatic scheme for FGF interactions with cells	61
14	Biological actions of HGF	66

Fig.	Title	Page
15	Schematic structure of gelatinases MMP-2 andMMP-9	69
16	Mechanism of angiogenesis inhibitors	77
17	Structure of thrombospondin	78
18	Aminoacid sequence of angiogenin	88
19	Correlation between Angiogenin expression and survival time	104
20	Real-time PCR steps	109
21	Steps of insitu hybridization	110
22	Western blot technique	111
23	Illustrative diagram of protein microarray	112
24	ELISA technique	113
25	Potential strategies for angiogenesis-based cancer therapies	115

Acknowledgement

First of all I thank God for blessing this work and giving me the power to finish it, as part of His generous help throughout my life.

I wish to express my over lasting gratitude and sincere appreciation to **Prof. Sawsan Said Hafez**, Professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for giving me the privilege of working under her supervision as well as her exert touches, the indispensable guidance and advice and the too much care she provided me.

My deepest thanks to **Dr. Manal Mohamed Abd Al-Aziz**, Assistant professor of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for her generous cooperatin, great support and unlimited willigness during performing this work.

Many thanks to **Dr. Eman Saleh El-Hadidi** Lecturer of Clinical and Chemical Pathology, Faculty of Medicine, Ain Shams University, for

her great help and support, her continuous guidance and for offering me much of her time and effort.

Lastly but not the least, I'm very thankful to all my family specially my Parents for their continuous encouragement and great support.

Magy Samir

INTRODUCTION

Angiogenesis refers to the development of new blood vessels from preexisting vasulature. The angiogenesis process is fundamental to tumor growth. It is implicated in the initial progression from a premalignant tumor to a cancer, invasion of cancer cells into the circulation and growth of micrometastasis into frank metastatic lesions (*Hanahan and Folkman, 1996*).

The process of angiogenesis is triggered by angiogenic factors derived from tumor cells and infiltrative cells such as; macrophage and fibroblasts. The best-characterized angiogenesis factors include angiogenin, vascular endothelial growth factor, interleukin-8, fibroblast growth factor and others. Their action is antagonized by many antiangiogenic factors, such as angiostatin, endostatin, thrombospondin-1 and -2 and others (*Takahashi et al., 1996*).

Angiogenin is a potent blood vessel inducing protein that was originally purified from the human colon carcinoma cell line. It was later found in normal human serum, and its mRNA was found to be expressed in human tumor cells, as well as non malignant cells such as peripheral blood cells, vascular endothelial cells and fibroblasts. Increased angiogenin expression in tumor tissue, and its serum

concentration was observed in patients with various tumors such as; pancreatic carcinoma, urothelial carcinoma, colorectal carcinoma and others (*Dosquet et al., 1997 and Miyake et al., 1999*).

Concerning colorectal carcinoma, serum angiogenin concentration is found to be higher than that in nonneoplastic diseases. The mean serum angiogenin concentration is positively correlated with the tumor progression and cancer stage, whereas, after cancer resection it decreases to nearly normal level. Accordingly, serum angiogenin could be useful as a diagnostic marker for stage grouping and Dukes classification as a result of cancer cell invasion. Moreover, its assay could be potentially useful for long time follow-up of patients as an early marker of recurrence (*Shimoyoma et al., 1999 and Shimoyoma et al., 2002*).

Aim of the study

To study the role of angiogenic factors specially angiogenin as a diagnostic and prognostic marker in colorectal carcinoma mainly and in other carcinomas.

I. COLORECTAL CANCER

A. Epidemiology and Risk Factors of Colorectal Cancer:

1. Incidence

Colorectal cancer is a common and lethal disease. The number of patients with colorectal cancer has been increased in the last years (*Cole, 1999*). It is the fourth commonest form of cancer occurring world wide, with an estimated 9% of all cancers in men and 10.1% in women. In western countries it represents 12.6% of all cancers in men and 14.1% in women (*Cole, 1999 and Peter et al., 2000*).

Colorectal cancer is frequent in the population of equatorial Africa and Southeast of Asia. It has been noted frequently that migrants from low risk areas to higher risk areas tend overtime to acquire similar incidence of large bowel malignancy like that of the native population, which led some epidemiologists to postulate that the cause of this cancer is not racial or genetic but environmental (*Cole, 1999*).

Soliman and his colleagues (1999) found that in Egypt, colorectal cancer represents 12% for male and 11.5% for female cancers respectively. An individual with no specific risk factors has a lifetime chance of developing colorectal cancer approaching 6%.